We are seeking to determine the effects of potassium supplementation vs placebo for 6 weeks on the renin-angiotensin-aldosterone axis and also endothelial function in subjects with 10-20% 10 year cardiovascular risk.
Conditions
Interventions
Trade Name: SLOW-K
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Sponsors
Belfast Health and Social Care Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 50–70 years old with a 10-20% cardiovascular disease risk , (BMI) 60), a treated BP 100mmol/24hrs. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Exclusion - history of renal or cardio vascular disease,fasting glucose greater than or equal to 7mmol/l, interfering medications with the RAAS axis (namely diuretics, ACE inhibitors, angiotensin receptor blockers, aldosterone antagonists, calcium blockers or beta-blockers). Patients on HRT will also be excluded. Given the age of inclusion, pregnancy is unlikely however pregnant or lactating women will also be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine in a randomised single blinded crossover study the effect of potassium supplementation on global endothelial function;Secondary Objective: To determine the effect of potassium supplementation on the renin-aldosterone axis and on markers of vascular inflammation;Primary end point(s): Global endothelial function as assessed by pulse wave analysis at baseline and after salbutamol and GTN stimulation tests | — |
Countries
United Kingdom
Outcome results
None listed